During the past decade, Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt. conducted 25 clinical trials. In the 10-year time frame, 25 clinical trials started and 18 clinical trials were completed, i.e. on average, 72% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 6 clinical trials were completed. i.e. 42.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt." #1 sponsor was "Hoffmann-La Roche" with 23 trials, followed by "Arbeitsgemeinschaft medikamentoese Tumortherapie" with 15 trials sponsored, "EMD Serono Research & Development Institute, Inc." with 3 trials sponsored, "Genentech, Inc." with 2 trials sponsored and "Pfizer" with 2 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt." #1 collaborator was "Roche Pharma AG" with 5 trials as a collaborator, "Sanofi" with 4 trials as a collaborator, "Breast International Group" with 3 trials as a collaborator, "Celgene Corporation" with 3 trials as a collaborator and "Genentech, Inc." with 3 trials as a collaborator. Other collaborators include 27 different institutions and companies that were collaborators in the rest 33 trials.

According to Clinical.Site data, the most researched conditions in "Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt." are "Breast Cancer" (9 trials), "Acute Myeloid Leukemia" (3 trials), "Chronic Myelomonocytic Leukemia" (2 trials), "Diffuse Large B-Cell Lymphoma" (2 trials) and "Gastric Cancer" (2 trials). Many other conditions were trialed in "Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt." in a lesser frequency.

Most popular intervention types in "Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt." are "Drug" (53 trials), "Radiation" (4 trials), "Biological" (3 trials), "Other" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Atezolizumab" (8 trials), "Rituximab" (6 trials), "Bevacizumab" (5 trials) and "Capecitabine" (5 trials). Other intervention names were less common.

The vast majority of trials in "Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt." are 49 trials for "All" genders and 5 trials for "Female" genders.

Currently, there are NaN active trials in "Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt.". undefined are not yet recruiting, 6 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 30 completed trials in Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt., undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt., 6 "Phase 1" clinical trials were conducted, 23 "Phase 2" clinical trials and 29 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".